Navigation Links
Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
Date:4/14/2008

Poster Presented at the 2008 AACR Annual Meeting

SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 American Association of Cancer Research (AACR) Annual Meeting being held April 12 - 16 in San Diego.

In the poster titled "The inhibition of radiation repair by ranpirnase +/- I-buthionine sulfoximide on lung cancer," Dr. Lee provided pre-clinical evidence that ONCONASE +/- I-buthionine sulfoximide significantly increased the radiation-induced growth delay of lung tumors in vivo without increases in skin reaction, compared to radiation alone. Additionally, in vivo and in vitro data presented indicated that ONCONASE significantly increased apoptosis (programmed cell death) in several human non-small cell lung cancer (NSCLC) cell lines (A549, NCI-H1975 and HOP-62). Dr. Lee and his team of researchers also showed that the radiation repair mechanisms known as sub-lethal damage repair (SLDR) and potentially lethal damage repair (PLDR), which lead to radiation resistance in tumors, were significantly inhibited by ONCONASE in vitro.

"Our research suggests potential utility of ONCONASE as a radiotherapy enhancer for the treatment of NSCLC patients," said Dr. Lee. "It is important to overcome PLDR as it can ultimately lead to radiation resistance. One of our key findings is the inhibiting impact of ONCONASE on the PLDR mechanism, which is a pre-requisite to developing a radiotherapy enhancer."

Kuslima Shog
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...RNewswire/ -- Axentis Pharma AG has,initiated a cl...lerability,of a new therapeutic formulation for th...c fibrosis patients. The new formulation allows an...ectly to the site of,infection. The forthcoming tr... doses of the new drug. Initial results are expect...
(Date:9/4/2008)...cation for Targeted Therapies That En...TON BEACH, Calif., and AMSTERDAM, Netherlands, Sep...lecular cancer diagnostics,today announced the la...,allows physicians to quantitatively determine the...ER), progesterone receptor (PR) and Human Epiderma...
(Date:9/3/2008)...g Children Studied. Wrong,Conclusions Reached., N...ters for Disease,Control and Prevention (CDC) stud...he MMR vaccine and autism. The National Autism Ass...pel the growing public concern over a,vaccine-auti...ing design,and methodology., For years, parents h...
(Date:9/3/2008)...chronically infected Hepatitis C,patients strongly... in 2008, - Study is the first to show a statist...effect of therapeutic Hepatitis C vaccination, -...a second generation, vaccine formulated with Inte... activation, VIENNA, Austr...
Breaking Medicine Technology:Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Agendia Launches TargetPrint(R) for Breast Cancer Patients 2CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4New approach builds better proteins inside a computer 863 1New approach builds better proteins inside a computer 863 2New approach builds better proteins inside a computer 863 3New approach builds better proteins inside a computer 863 4Changing the global dietary environment 861 1Changing the global dietary environment 861 2Deadlines for 2007 National Soybean Rust Symposium fast approaching 859 1Deadlines for 2007 National Soybean Rust Symposium fast approaching 859 2Tolerance to inhalants may be caused by changes in gene expression 857 1Tolerance to inhalants may be caused by changes in gene expression 857 2
...7 - EPIX,Pharmaceuticals, Inc. (NASDAQ: EPIX) toda...X-00023, a novel long-acting 5-HT1A agonist,was f...l New,Clinical Drug Evaluation Unit (NCDEU) Meetin... by the National Institutes of,Health and the Amer...presentation highlighted data from a randomized,d...
... Prolexys,Pharmaceuticals and announced today a pu...ve small molecule anti-tumor agent,erastin. Prole...omics technology to understand the mechanism of ac...he June 14, 2007 issue,of the journal Nature revea...endent anion channels (VDACs) -- a novel target fo...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3
(Date:9/8/2008)...aser scalpels, arthroscopic,surgery, genomic resea...rinary medicine is quickly expanding into new high...e benefit; it,s improving medicine for,people, too... care for their pets to,treat diseases like diabet... according to the American Veterinary Medical Asso...
(Date:9/8/2008)...zine examines Iraq and Afghanistan veterans, strug..., Washington, DC (PRWEB) S...by veterans of the Iraq and Afghanistan wars about... addiction disorders are featured in the current i...ublication of the National Council for Community B...
(Date:9/7/2008)...f older patients successfully treated for colorect...le to detect any recurrence of cancer. The study, ... , a peer-reviewed journal of the American Cancer ...monitoring of colorectal cancer survivors could af...y curative surgery for colorectal cancer have an i...
(Date:9/7/2008)... appear to lower a man,s PSA level, the blood biom...her a man is at risk of prostate cancer. , But t.... 8 in the journal Cancer , caution that men shou... prostate cancer just yet. , "We showed that me...rin and other non-steroidal anti-inflammatory drug...
Breaking Medicine News(10 mins):Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:Helping Veterans in Our Communities 2Health News:Helping Veterans in Our Communities 3Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Common painkillers lower levels of prostate cancer biomarker 2
...ly hurt in a farm accident, claimed a chance for s... The 16 year old teenage boy had suffered grave in... helicopter. Insp Roger McConnell, who accompanied...n't want to take all the credit, because the fire ...
...arize and improve collaboration regarding the emer...se, more specifically bird flu//, a training progr...scenario involving transfer of a suspected case of...er was simulated. The Baptist Hospital and the Qu...
...eat promise for new treatments for many conditions... types of adult tissue//. But the human embryo ste... scientists believe the human testicle may provide...or stem cell research. A German team has describ...
...g sensitive to noise, and do not like it much! Acc...noisy surroundings// may face an increased risk of... revealed that the chances of urban middle-aged ad...and amidst a lot of din, stood a 46 percent chance...
Other Medicine News:Health News:Human Testicular Cells Would Help In Stem Cell Research 2
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
...WideBiter Punch series facilitates fast and effect... smooth, anatomically shaped meniscal rim. The fla...e to access even the tightest joint spaces. Made i...f engineering experience in arthroscopy hand instr...
Medicine Products: